Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last721 to 740 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With at Least One Serious Adverse Event (SAE) | 263 of 6,352 266 of 6,366 | -0.0 points -0.7 to 0.7 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs) | 849 of 6,352 824 of 6,366 | 0.4 points -0.8 to 1.6 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Occurrences of Death | 12 of 6,352 17 of 6,366 | -0.1 points -0.3 to 0.1 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants Who Withdrew Due to an AE | 15 of 6,352 20 of 6,366 | -0.1 points -0.3 to 0.1 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With at Least One New Onset Chronic Diseases (NOCDs) | 36 of 6,352 23 of 6,366 | 0.2 points -0.0 to 0.5 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With ≥ Severe Solicited Local and Systemic Reaction | 47 of 6,352 62 of 6,366 | -0.2 points -0.6 to 0.1 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With at Least One Immediate Complaints | 272 of 6,352 184 of 6,366 | 1.4 points 0.7 to 2.0 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With ≥ Severe Related Unsolicited Reactions | 1 of 6,352 3 of 6,366 | -0.0 points -0.1 to 0.0 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With ≥ Severe Related Solicited Reactions | 28 of 6,352 51 of 6,366 | -0.4 points -0.6 to -0.1 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With ≥ Severe Unsolicited TEAEs | 33 of 6,352 34 of 6,366 | -0.0 points -0.3 to 0.2 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): deaths from any cause | 12 of 6,352 17 of 6,366 | -0.1 points -0.3 to 0.1 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): serious adverse events | 263 of 6,352 266 of 6,366 | -0.0 points -0.7 to 0.7 | 12,718 | NCT03739112 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly |
| Patients Screened for HIV vs Patients Screened for HCV: Opt-out | 1,479 of 6,350 1,487 of 6,350 | -0.1 points -1.6 to 1.3 | 12,700 | NCT03595527 Universal HIV Screening and Targeted HCV Screening in Emergency Department |
| Conventional EMS CPR vs Bundled EMS CPR: Number of Participants With Survival to Hospital Discharge | 594 of 6,201 707 of 6,469 | -1.3 points -2.4 to -0.3 | 12,670 | NCT02540629 Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City |
| Conventional EMS CPR vs Bundled EMS CPR: Number of Participants With Good Neurological Recovery at Discharge | 334 of 6,201 441 of 6,469 | -1.4 points -2.3 to -0.6 | 12,670 | NCT02540629 Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City |
| Conventional EMS CPR vs Bundled EMS CPR: deaths from any cause | 5,607 of 6,201 5,762 of 6,469 | 1.3 points 0.3 to 2.4 | 12,670 | NCT02540629 Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City |
| Acetylsalicylic Acid vs Placebo: serious adverse events | 1,266 of 6,270 1,311 of 6,276 | -0.7 points -2.1 to 0.7 | 12,546 | NCT00501059 A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease |
| Insulin Glargine vs Standard Care: Total Mortality (All Causes) | 951 of 6,264 965 of 6,273 | -0.2 points -1.5 to 1.1 | 12,537 | NCT00069784 The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) |
| Insulin Glargine vs Standard Care: Number of Patients With First Occurrence of Any Type of Cancer | 559 of 6,264 561 of 6,273 | -0.0 points -1.0 to 1.0 | 12,537 | NCT00069784 The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) |
| E-MOTIVE Intervention vs Usual Care: Compliance With MOTIVE Bundle | 3,791 of 4,158 1,623 of 8,351 | 71.7 points 70.5 to 72.9 | 12,509 | NCT04341662 A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=37
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03739112-13c037c8",
"title": "Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With at Least One Serious Adverse Event (SAE)",
"summary": "263 of 6352 against 266 of 6366; risk difference -0.0 points, 95% interval -0.7 to 0.7; NCT03739112, Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly",
"record": "/library/comparisons/NCT03739112-13c037c8",
"nct_id": "NCT03739112",
"kind": "outcome",
"participants": 12718,
"risk_difference": {
"value": -0.00038019793439802996,
"lower": -0.007340194565206024,
"upper": 0.006579711871167111
},
"group_1": "263 of 6,352",
"group_2": "266 of 6,366",
"difference": "-0.0 points",
"interval": "-0.7 to 0.7",
"trial_title": "Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly"
},
{
"id": "NCT03739112-4e5f9fb1",
"title": "Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs)",
"summary": "849 of 6352 against 824 of 6366; risk difference 0.4 points, 95% interval -0.8 to 1.6; NCT03739112, Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly",
"record": "/library/comparisons/NCT03739112-4e5f9fb1",
"nct_id": "NCT03739112",
"kind": "outcome",
"participants": 12718,
"risk_difference": {
"value": 0.0042210527273748855,
"lower": -0.007531375116861071,
"upper": 0.015975191767790997
},
"group_1": "849 of 6,352",
"group_2": "824 of 6,366",
"difference": "0.4 points",
"interval": "-0.8 to 1.6",
"trial_title": "Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=38",
"request_id": "Vchb3TXi6wJ0OOuA"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant